Endogenous Sex Hormones And The Risk Of Prostate Cancer: A Prospective Study

Main Category: Prostate / Prostate Cancer
Also Included In: Urology / Nephrology;  Endocrinology;  Clinical Trials / Drug Trials
Article Date: 02 Mar 2008 - 0:00 PDT

email to a friend   printer friendly   opinions  

UroToday.com- Relationship between Endogenous Sex Hormones and Prostate Cancer Not Demonstrated in Prospective Study: Previous epidemiologic studies relating serum hormone levels to prostate cancer (CaP) risk have been inconclusive. In the International Journal of Cancer, Dr. Weiss and associates report a large nested case-control study including 727 cases and 889 controls using pre-diagnostic serum samples in the prospective Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. They examined associations between androstenedione (4-A), testosterone (T), sex hormone-binding globulin (SHBG), and 3 androstanedio glucuronide (3-diolG) with the risk of CaP. This study had the benefit of a large size that would permit evaluation of androgen-associated risks in relation to CaP aggressiveness and to consider risks in population subgroups.

The PLCO screening trial is a two-armed, randomized controlled trial designed to evaluate the effectiveness of prostate, lung, colorectal, and ovarian cancer screening and to investigate etiologic factors and early markers of cancer. Case diagnosis followed an elevated PSA (57%), an abnormal rectal exam (14%), and both (17%). Most serum hormone levels were not correlated with PSA in cases or controls, however T:SHBG was correlated with PSA in controls. Although risks tended to increase with greater total, free, and bioavailable T, and to decrease with greater SHBG, these findings were not statistically significant. T:SHBG ratio, however, was associated with increased risk for CaP especially in men age 65 years and older.

In summary, there is not significant convincing evidence of a relationship between serum sex hormones and prostate cancer.

Weiss JM, Huang WY, Rinaldi S, Fears TR, Chatterjee N, Hsing AW, Crawford ED, Andriole GL, Kaaks R, Hayes RB.

Int J Cancer. 2008 Jan 2 [Epub ahead of print]
doi:10.1002/ijc.23326

Reported by UroToday.com Contributing Editor Christopher P. Evans, MD

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

----------------------------
Copyright © 2007 - UroToday
Reproduced for Medical News Today with permission of UroToday.
----------------------------

• Additional
• References
• Citations